News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Business Standard Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Cormorant Asset Management, LP and Bihua Chen have reported a significant ownership stake of 9.17% in Bright Minds Biosciences Inc. This beneficial ownership translates to 900,000 Common Shares out of 9,812,061 shares outstanding as of May 15, 2026. The reporting persons share voting and …
Bright Minds Biosciences (TSX:DRUG) is gaining attention due to progress in its lead neuroscience program, BMB, a selective serotonin receptor-targeting candidate for difficult-to-treat seizure disorders. The company reported positive topline results from its BREAKTHROUGH study, demonstrating anti-seizure activity and a favorable safety profile, and …
Adage Capital Management, L.P. and its affiliated entities have reported a beneficial ownership of 3.41% in Bright Minds Biosciences Inc. (DRUG) through a Schedule 13G/A filing. This stake, totaling 335,000 common shares, reflects shared voting and dispositive power among the reporting persons, including Robert …
Bright Minds Biosciences Inc (CN:DRUG) shares experienced a decline due to weakening investor sentiment in the biotechnology sector, coupled with increased development risks inherent in clinical-stage companies. The company, which focuses on psychedelic-inspired therapies for neurological and psychiatric disorders, faces challenges including clinical trial …
This article provides a stock analysis of Bright Minds Biosciences (CNSX:DRUG), highlighting its valuation, future growth prospects, past performance, and financial health. The company is trading significantly below its estimated fair value and its revenue is forecast to grow, but it faces risks such …
Bright Minds Biosciences Inc (CN:DRUG) saw its Canadian-listed shares jump 4.05% to C$114 on August 6, 2026, though this increase is attributed to extremely low trading volume (302 shares) rather than any new company news or market re-evaluation. The article emphasizes that the movement …
Bright Minds Biosciences (NASDAQ:DRUG) is scheduled to release its Q3 2026 earnings before market open on Thursday, August 13th. Analysts anticipate a loss of $1.2831 per share. The company previously reported a loss of $0.80 per share, exceeding analyst estimates by $0.06.
This article analyzes Bright Minds Biosciences Inc. (NASDAQ: DRUG) using AI models to provide trading strategies. It highlights a near-term strong sentiment influencing a mid-term neutrality toward a long-term positive bias, noting a mid-channel oscillation pattern. The analysis offers specific entry, target, and stop-loss …
This article provides a financial overview of Drugs Made In America Acquisition Corp. (DMAAU) as presented on TradingView. It indicates that the market is closed for this stock with no recent trades. The page offers access to financial statements, statistics, dividends, earnings, and segment …
Bright Minds Biosciences Inc. (DRUG) shows a current price of 77.770 USD with a 5.41% increase, and a market cap of 763.08M. Analyst ratings are predominantly "Buy" with a target price of 148.557 USD, indicating a 102.78% upside. The company is focused on developing …
This page provides financial data and an overview for Drugs Made In America Acquisition Corp. (DMAAR) on TradingView. It indicates that the market is closed, with no current trades. Users can find fundamentals, statistics, dividend information, earnings, and segment performance for the company.
Search by ticker symbol or company name and select a result to open its chart.